Yes, why not market sensitive? Just a quick search below comes up with 4 concrete examples of Orphan Drug Designation being granted and EACH ONE IS MARKET SENSITIVE as marked by the ASX. I could go on because there are plenty more but why the inconsistency. So what does Orphan Drug status do, it usually means tax credits for trials, a market exclusive period and less or no fees throughout the drug approval process.
Mesoblast MSB 15/02/24, Neuren NEU 3/9/21, Noxopharm NOX 4/10/23, Argenica AGN 15/11/23 All market sensitive but not CUV 29/4/24?
Ann: SCENESSE European Orphan Drug Designation for XP, page-5
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.69 |
Change
0.070(0.45%) |
Mkt cap ! $786.1M | |||
| Open | High | Low | Value | Volume |
| $15.68 | $15.98 | $15.58 | $1.543M | 98.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 256 | $15.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.77 | 256 | 1 |
View Market Depth
| Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$15.70 |
Change
0.070 ( 0.36 %) |
||||
| Open | High | Low | Volume | ||
| $15.68 | $15.97 | $15.60 | 6072 | ||
| Last updated 15.59pm 28/05/2024 ? | |||||
| CUV (ASX) Chart |